Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

NCT03646994 · clinicaltrials.gov ↗

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Crizotinib

Sponsor

Hunan Province Tumor Hospital